Buy CJC-1295 No DAC Peptide Kit (10 Vials) – Premium Modified GRF 1-29 for Research Applications

CJC-1295 No DAC (Modified GRF 1-29) is a highly purified synthetic growth hormone-releasing hormone (GHRH) analog developed for laboratory investigations involving pulsatile endocrine signaling and downstream growth factor pathways. Unlike the long-acting DAC variant, CJC-1295 No DAC is designed to support short-duration receptor activation, making it valuable for researchers studying physiological growth hormone pulse patterns under controlled experimental conditions.

Available in convenient 10-vial kits containing either 2 mg or 5 mg per vial, this research peptide is manufactured to stringent quality standards and undergoes extensive analytical verification to ensure batch-to-batch consistency.

Product Highlights

• 10 vacuum-sealed lyophilized vials per kit
• Available in 2 mg and 5 mg strengths
• ≥99% purity verified by HPLC analysis
• Mass spectrometry identity confirmation
• Excellent stability under recommended storage conditions
• Transparent Certificate of Analysis (COA)
• Research-grade manufacturing standards
• Intended exclusively for laboratory research

What Is CJC-1295 No DAC?

CJC-1295 No DAC, also known as Modified GRF 1-29, is a synthetic peptide derived from the first 29 amino acids of endogenous growth hormone-releasing hormone. Through four strategic amino acid substitutions, the molecule exhibits improved resistance to enzymatic degradation while preserving affinity for GHRH receptors.

These modifications distinguish Modified GRF 1-29 from native GHRH and Sermorelin, providing researchers with an optimized peptide suitable for investigating pulsatile growth hormone secretion and associated signaling pathways.

Unlike CJC-1295 with DAC, which contains a Drug Affinity Complex that extends circulation time through albumin binding, CJC-1295 No DAC does not contain this component and is therefore frequently utilized in experimental models emphasizing short-term receptor activation.

Mechanism of Action

CJC-1295 No DAC acts as a GHRH receptor agonist. By interacting with receptors located on pituitary somatotroph cells, researchers study the physiological processes associated with growth hormone release and downstream insulin-like growth factor-1 (IGF-1) signaling.

Its short-acting profile has made it a widely investigated compound for understanding endocrine rhythm regulation and growth factor-mediated cellular responses.

Primary Areas of Research

Pulsatile Growth Hormone Signaling

Researchers utilize Modified GRF 1-29 to investigate natural growth hormone secretion patterns and endocrine feedback mechanisms.

IGF-1 and Cellular Signaling Pathways

Experimental models explore downstream pathways involving insulin-like growth factor-1 and related anabolic signaling networks.

Tissue Regeneration Research

Preclinical investigations have evaluated the relationship between growth factor signaling and cellular repair processes, extracellular matrix remodeling, and collagen synthesis.

Metabolic Studies

CJC-1295 No DAC has been used in studies examining body composition, lipid metabolism, and nitrogen balance pathways.

Sleep and Circadian Rhythm Research

Scientists have investigated the interaction between endogenous growth hormone release and sleep architecture, particularly during slow-wave sleep.

Healthy Aging Models

Age-associated changes in growth hormone secretion continue to be an active area of endocrine research, making Modified GRF 1-29 a useful investigational tool.

CJC-1295 No DAC vs. CJC-1295 With DAC

Product Specifications

Kit Configurations

20 mg Research Kit

• 10 vials × 2 mg each
• Total peptide content: 20 mg

50 mg Research Kit

• 10 vials × 5 mg each
• Total peptide content: 50 mg

Quality Assurance

Every production batch undergoes comprehensive analytical testing, including:

• High-performance liquid chromatography (HPLC) purity verification
• Mass spectrometry identity confirmation
• Appearance and consistency evaluation
• Batch traceability controls
• Certificate of Analysis availability

These procedures help ensure exceptional consistency and reliability for demanding research applications.

Storage Guidelines

To maintain molecular integrity:

• Store lyophilized vials between 2°C and 8°C.
• Protect from excessive heat, humidity, and direct sunlight.
• Avoid repeated freeze-thaw cycles.
• Keep vials sealed until use.
• Handle reconstituted material according to established laboratory protocols.

Under recommended conditions, lyophilized material may remain stable for extended periods.

Why Researchers Choose CJC-1295 No DAC

• Optimized GHRH analog structure
• Enhanced resistance to enzymatic degradation
• High receptor affinity
• Suitable for pulsatile endocrine research
• Available in multiple concentrations
• Stringent analytical verification
• Reliable batch consistency
• Convenient 10-vial packaging

Frequently Asked Questions

What is Modified GRF 1-29?

Modified GRF 1-29 is another name for CJC-1295 No DAC. It is a synthetic GHRH analog containing four amino acid substitutions that improve stability compared with native GHRH.

What is the difference between CJC-1295 with DAC and without DAC?

The primary distinction is the presence of the Drug Affinity Complex. The DAC version exhibits prolonged activity due to albumin binding, whereas the No DAC version is designed for short-duration receptor interaction.

Is CJC-1295 No DAC the same as Sermorelin?

No. Although both are derived from growth hormone-releasing hormone sequences, Modified GRF 1-29 contains structural modifications that improve resistance to enzymatic degradation.

What purity level does this product provide?

Each batch is verified to achieve at least 99% purity through HPLC analysis.

Is a Certificate of Analysis available?

Yes. Certificates of Analysis are available to provide transparency regarding purity and batch quality.

What research compounds are commonly studied alongside CJC-1295 No DAC?

Researchers frequently investigate related compounds such as:

• Ipamorelin
• Sermorelin
• Tesamorelin
• GHRP-2
• GHRP-6
• MK-677

Study designs and methodologies vary depending on the objectives of individual investigations.

Does CJC-1295 No DAC have approved therapeutic applications?

No. CJC-1295 No DAC is an investigational compound and has not been approved by the FDA, EMA, Health Canada, or other major regulatory agencies for human or veterinary use.

Scientific References

• Jette L, Leger R, Thibaudeau K, et al. Human Growth Hormone-Releasing Factor Analogues.
• Teichman SL, Neale A, Lawrence B, et al. Clinical Pharmacology of CJC-1295.
• Dragic T, et al. Investigations of Growth Hormone-Releasing Hormone Analogs.
• Endocrine and peptide signaling literature concerning growth hormone and IGF-1 pathways.

Conclusion

CJC-1295 No DAC (Modified GRF 1-29) is a highly purified GHRH analog widely utilized in endocrine and growth factor research. Through enhanced resistance to enzymatic degradation and preservation of short-duration receptor activity, it provides investigators with a valuable tool for studying pulsatile growth hormone signaling and related biological pathways.

Available in convenient 20 mg and 50 mg configurations and supported by rigorous analytical testing, this premium research peptide delivers the consistency and quality demanded by modern laboratories.

Research Use Only

CJC-1295 No DAC (Modified GRF 1-29) is intended strictly for laboratory research purposes. This product is not approved by the FDA, EMA, Health Canada, or any other regulatory authority for human or veterinary use. It is not intended to diagnose, treat, cure, or prevent any disease.

Related Research Peptides

• Sermorelin 2-5mg*10 vials
• Ipamorelin: 2mg*10vials